R Squared’s Neuropace NPCE Stock Holding History

R Squared’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,927	Closed	-$133K	–	653
2025 Q3	$133K	Buy	+12,927	New	+$122K	0.06%	423
2025 Q1	–	Sell	-1,411	Closed	-$15.8K	–	1075
2024 Q4	$15.8K	Buy	+1,411	New	+$12.3K	0.02%	987

Other funds holding NPCE

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

R Squared's NPCE Position: Q4 2025 in Review

R Squared sold out of Neuropace (NPCE) in Q4 2025, closing a stake of 12,927 shares — an estimated $133K sold.

R Squared first reported a position in NPCE in Q4 2024 and held it in 2 quarters. The position peaked at $133K in Q3 2025. 100 funds tracked by Wall St. Rank hold NPCE as of Q4 2025.

R Squared reported no remaining Neuropace position as of Q4 2025 after selling out during the quarter.
R Squared sold 12,927 Neuropace shares in Q4 2025, an estimated $133K.
R Squared first reported a position in Neuropace in Q4 2024 and held it in 2 quarters.
R Squared's Neuropace position peaked at $133K in Q3 2025.
100 funds tracked by Wall St. Rank held Neuropace as of Q4 2025.

Based on R Squared's 13F filing for Q4 2025, filed 30 Jan 2026.